Float Short %

11.52

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

EPS Last/This Y

0.62

EPS This/Next Y

0.33

Price

9.35

Target Price

16.4

Analyst Recom

1.2

Performance Q

19.54

Relative Volume

1.65

Beta

1.07

Ticker: BCRX

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	BCRX	10.73	0.30	0.21	36586
2025-06-03	BCRX	11.2	0.30	0.18	36639
2025-06-04	BCRX	11.02	0.30	0.05	37009
2025-06-05	BCRX	10.98	0.30	0.01	37111
2025-06-06	BCRX	11.04	0.30	0.04	37103
2025-06-09	BCRX	11.1	0.30	0.49	37145
2025-06-10	BCRX	11.02	0.30	0.04	37187
2025-06-11	BCRX	10.6	0.30	0.67	37194
2025-06-12	BCRX	10.4	0.30	2.89	37245
2025-06-13	BCRX	10.36	0.31	0.37	37470
2025-06-16	BCRX	10.29	0.31	0.06	37474
2025-06-17	BCRX	9.95	0.31	0.70	37570
2025-06-18	BCRX	9.97	0.30	0.09	37735
2025-06-20	BCRX	10.1	0.30	0.41	38089
2025-06-23	BCRX	9.91	0.34	0.53	27233
2025-06-24	BCRX	9.91	0.34	0.98	27781
2025-06-25	BCRX	9.73	0.35	0.58	28016
2025-06-26	BCRX	9.65	0.35	0.04	28375
2025-06-27	BCRX	9.36	0.35	0.10	28740
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	BCRX	10.74	218.1	-	0.19
2025-06-03	BCRX	11.19	215.0	-	0.17
2025-06-04	BCRX	11.02	215.0	-	0.17
2025-06-05	BCRX	10.98	215.0	-	0.17
2025-06-06	BCRX	11.04	215.0	-	0.17
2025-06-09	BCRX	11.11	215.0	-	0.17
2025-06-10	BCRX	11.02	215.0	-	0.17
2025-06-11	BCRX	10.60	215.0	-	0.17
2025-06-12	BCRX	10.40	215.0	-	0.17
2025-06-13	BCRX	10.36	218.1	-	0.19
2025-06-16	BCRX	10.29	218.1	-	0.19
2025-06-17	BCRX	9.96	218.1	-	0.19
2025-06-18	BCRX	9.96	218.1	-	0.19
2025-06-20	BCRX	10.10	218.1	-	0.19
2025-06-23	BCRX	9.90	218.1	-	0.19
2025-06-24	BCRX	9.92	218.1	-	0.19
2025-06-25	BCRX	9.73	218.1	-	0.19
2025-06-26	BCRX	9.65	218.1	-	0.19
2025-06-27	BCRX	9.35	218.1	-	0.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	BCRX	-0.08	5.62	10.46
2025-06-03	BCRX	-0.08	5.62	10.46
2025-06-04	BCRX	-0.08	5.62	10.46
2025-06-05	BCRX	-0.08	5.62	10.46
2025-06-06	BCRX	-0.08	5.62	10.46
2025-06-09	BCRX	-0.08	5.66	10.46
2025-06-10	BCRX	-0.08	5.66	10.46
2025-06-11	BCRX	-0.08	5.66	11.98
2025-06-12	BCRX	-0.08	5.66	11.98
2025-06-13	BCRX	-0.08	5.66	11.98
2025-06-16	BCRX	-0.08	5.65	11.98
2025-06-18	BCRX	0.00	5.65	11.98
2025-06-20	BCRX	0.00	5.65	11.98
2025-06-23	BCRX	0.00	5.70	11.99
2025-06-24	BCRX	0.00	5.70	11.99
2025-06-25	BCRX	0.00	5.70	11.99
2025-06-26	BCRX	0.00	5.70	11.52
2025-06-27	BCRX	0.00	5.70	11.52
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.07

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

Institutional Transactions

5.7

Beta

1.07

Average Sales Estimate Current Quarter

149

Average Sales Estimate Next Quarter

156

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

53.2

Max Drawdown 5-Year %

-79.1

Target Price

16.4

P/E

Forward P/E

22.39

PEG

P/S

3.89

P/B

P/Free Cash Flow

EPS

-0.26

Average EPS Est. Cur. Y

0.19

EPS Next Y. (Est.)

0.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.62

Relative Volume

1.65

Return on Equity vs Sector %

-12.1

Return on Equity vs Industry %

4.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.25

EBIT Estimation

BioCryst Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 580

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

stock quote shares BCRX – BioCryst Pharmaceuticals, Inc. Stock Price stock today

news today BCRX – BioCryst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch BCRX – BioCryst Pharmaceuticals, Inc. yahoo finance google finance

stock history BCRX – BioCryst Pharmaceuticals, Inc. invest stock market

stock prices BCRX premarket after hours

ticker BCRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: BCRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y